Skip to main content

Disorders of Ejaculation: AUA/SMSNA Guideline (2027)

In brief

Updated guideline adds clomipramine and glans injections for premature ejaculation

An update based on evidence reviews of 25 studies adds guidance on daily or on-demand clomipramine and hyaluronic acid injections into the glans for premature ejaculation; both require informed consent and a trained clinician. It also revises guidance on non-drug therapies and offers expert opinion on PDE5 inhibitors, while shared decision-making remains central.

Journal
The Journal of urology (Q1)
Published
17 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1c)
Authors
Alan W Shindel, David Rowland, Norma Varela, Rebecca S Holmes, Petar Bajic
PMID
43042700
DOI
10.1097/JU.0000000000005378

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 22 November 2026): AUA/SMSNA guideline on ejaculation disorders and treatment

Abstract

PURPOSE: The amendment of the Disorders of Ejaculation Guideline provides an update to the evidence-based guidance for clinicians on appropriate evaluation, diagnosis, and available treatments of premature ejaculation (PE) or delayedejaculation. MATERIALS AND METHODS: The Pacific Northwest Evidence-Based Practice Center utilized Ovid MEDLINE and Embase databases to search for studies published between January 1, 2020 and December 19, 2024. Search strategies that were developed for the original Disorders of Ejaculation guideline were employed. The search identified 727 abstracts, 89 of which met inclusion criteria. In 2025, NV HEATHRES. INC. extracted data and assessed the quality of the evidence for outcomes on 25 studies to inform statement updates. RESULTS: A statement on non-pharmacological therapies for the treatment of PE was revised to reflect new evidence that indicates that some of these therapies may be effective. A new Expert Opinion statement on the potential use of PDE5i for the treatment of PE was written. Although there was evidence to support 2 new statements on the use of daily or on-demand clomipramine or glans hyaluronic acid injection for the treatment of PE, the Panel emphasizes that these treatments are to be used in the context of patient informed consent and at the behest of a trained clinician. CONCLUSIONS: Although much of the evidence used to inform this Amendment supported existing statements, there was new data to support new statements on PDE5i, daily or on-demand clomipramine, and glans HA injection for the treatment of PE, although the latter 2 recommendations come with important caveats. Ultimately, the Panel recommends that shared decision-making should be the fundamental precept in the management of disorders of ejaculation regardless of the treatment option utilized.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.